Sterigenics International LLC has acquired Toxikon Europe N.V., the European division of Toxikon Corporation, a Bedford, Mass.-based preclinical contract research organization. Terms of the deal were not disclosed.
Toxikon Europe N.V. provides a suite of integrated analytical, material characterization and microbiological services to the pharmaceutical, medical device, and biologics industries. The company’s extractables and leachables (E&L) testing experience and database enhance the flexibility and speed with which its life science customers can bring their products to market, according to Sterigenics.
The acquisition provides a more comprehensive service offering and a platform for growth for Sterigenics International’s Nelson Labs business. Nelson Labs will now offer Toxikon Europe’s E&L capabilities to its customers around the world and in kind, offer Nelson Labs microbiological services to Toxikon Europe’s customers.
“Toxikon Europe’s geographic foothold and expert analytical testing platform enable our global expansion and ability to provide significantly greater value to customers,” said Michael B. Petras Jr., CEO of Sterigenics International. “We are excited to welcome a strong management team, with over 150 years of aggregate industry experience, and the highly trained Toxikon Europe employees to our company.”
Toxikon Europe’s capabilities are both complementary and additive to Nelson Labs’ existing testing portfolio.
As part of the deal, Nelson Labs and Toxikon USA will enter into a long-term supply arrangement under which Nelson Labs will outsource in-vivo biocompatibility to Toxikon USA.
(Source: Sterigenics International LLC)